A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
Clinical trial NCT07250646 · RECRUITING
Trial details
- NCT number
- NCT07250646
- Sponsor
- Aspera Biomedicines, Inc.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-21
- Primary completion
- 2027-10-01
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.